AcedrA BioPharmaceuticals
AcedrA BioPharmaceuticals is a Riyadh-based hybrid platform founded in 2017 that combines specialty pharmaceutical distribution with licensing, regulatory, early-access, and commercialization services for pharma and biotech companies seeking to enter the MENA region.
- Company typePrivate
- Founded2017
- HeadquartersRiyadh, Saudi Arabia
- Headcount51–100
- GTM typeB2B
- OfferingServices
What AcedrA BioPharmaceuticals does
AcedrA BioPharmaceuticals (legal entity: AcedrA Pharmaceutical Company LLC) is a privately held pharmaceutical services and specialty distribution company headquartered in Riyadh, Saudi Arabia, founded in 2017 to address unmet medical needs across the Middle East and North Africa. The company operates a hybrid platform that combines physical distribution of specialty pharmaceuticals, orphan drugs, and medical devices with a portfolio of professional services including licensing support, managed and early access programs, regulatory and medical affairs management, full agency commercialization, pharmacovigilance, and advisory/consultancy. It continuously monitors the clinical pipelines of over 1,000 global biotechnology and medical companies to identify therapeutics suitable for MENA market entry.
The business is organized into three units — Unmet Medical Needs, Unmet Commercial Needs, and Medical Technology — and operates from offices in Riyadh (headquarters and central logistics warehouse), Tunis (North Africa regional HQ), and Dubai (UAE office), serving customers in more than 8 MENA countries and shipping over 3 million units annually. Revenue is generated through multiple streams: licensing royalties, professional services fees for regulatory and managed-access work, managed services for full agency engagements, and distribution margin on sourced pharmaceuticals and medical devices, all priced via direct B2B negotiation with pharmaceutical and biotech partners and healthcare facilities. The company maintains a structured executive team (CEO Hosni STA, Chairman Bkheet ALDOSARI, CFO Amjad Qasem, CCO Layla WAHABI, GM Mesfer ALDOSARI), is opening an investor-facing capital channel, and is preparing to launch the AcedrA Institute, a digital knowledge platform for healthcare professionals.
AcedrA BioPharmaceuticals firmographics
Firmographics- Name
- AcedrA BioPharmaceuticals
- Legal name
- AcedrA Pharmaceutical Company LLC
- Website
- https://acedrarx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- AcedrA BioPharmaceuticals is a Riyadh-based hybrid platform founded in 2017 that combines specialty pharmaceutical distribution with licensing, regulatory, early-access, and commercialization services for pharma and biotech companies seeking to enter the MENA region.
- Ownership category
- akta.pro rank
AcedrA BioPharmaceuticals industry classification
Industry- Product category
- Pharmaceutical Services
- NAICS
- Professional, Scientific, and Technical Services (54), Other Scientific and Technical Consulting Services (54169)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Management Services (8741)
- akta.pro primary industry
- Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)
- akta.pro secondary industries
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Corporate Strategy Advisory (BPAHADAA)
Keywords
Where AcedrA BioPharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Riyadh
- HQ country
- Saudi Arabia
- HQ region
- Middle East
Offices4 records
Markets served
AcedrA BioPharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D
Revenue model
- Licensing Services: AcedrA provides licensing services to pharmaceutical companies seeking to enter or expand in the MENA market, facilitating the authorization of their products for distribution in the region.
- Managed & Early Access Programs: The company generates revenue through early access and managed access programs that enable patients in the MENA region to access treatments not yet commercially available, charging for program management and product sourcing services.
- Regulatory & Medical Affairs Management: AcedrA provides regulatory and medical affairs services to pharmaceutical companies, helping navigate regional regulatory requirements for product approval and market entry.
- Distribution & Supply Chain: The company distributes specialty pharmaceuticals, medical devices, and equipment to the MENA region, earning margin on products sourced from manufacturers and authorized distributors.
- Full Agency Management: AcedrA provides comprehensive agency management services for pharmaceutical companies, handling commercialization activities in the MENA region on behalf of product owners.
- Advisory & Consultancy: The company offers advisory and consultancy services to pharmaceutical and biotechnology companies seeking strategic guidance on market entry and operations in the MENA region.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
AcedrA BioPharmaceuticals product offering
Product offeringCore offering
AcedrA BioPharmaceuticals is a regional pharmaceutical services partner that helps pharmaceutical and biotechnology companies commercialize and provide access to their products across the MENA region. Its service portfolio spans in-licensing, early and managed access programs, regulatory and medical affairs, distribution and supply chain management, full agency management (commercializing products on behalf of partners), and strategic advisory services addressing unmet medical and commercial needs.
Product overview
AcedrA BioPharmaceuticals is a regional pharmaceutical services company serving the MENA region since 2017. The company offers a comprehensive suite of services organized around three core business units: the Unmet Medical Needs unit, the Unmet Commercial Needs unit, and the Medical Technology unit. The core service portfolio includes Licensing, Managed & Early Access Programs, Regulatory & Medical Affairs Management, Distribution & Supply Chain Management, Full Agency Management, and Advisory & Consultancy. The Access Sourcing unit handles distribution of specialty pharmaceuticals and medical devices, while Access Innovation serves as a hybrid platform for clinical and commercial success. AcedrA Institute is an upcoming digital knowledge platform for healthcare professionals. The company also provides pharmacovigilance services for drug safety monitoring. All services are delivered with a focus on making innovation affordable for patients and scientific communities in the Middle East and North Africa.
Differentiator
Problem solved
Functional benefit
Brands
- AcedrA Institute: A comprehensive digital platform providing healthcare professionals access to up-to-date information about therapeutics and medical technologies across various specialties.
Products and services
- Licensing Services In-licensing of pharmaceutical and biotech products for commercialization across MENA markets on behalf of manufacturer partners. Intended for pharma and biotech principals seeking regional market entry without a local affiliate.
- Early & Managed Access Programs Design and operation of early access and managed access programs that enable patients to receive pharmaceutical products before full commercial availability. Intended for pharma and biotech principals and the healthcare providers and patients they serve across MENA.
- Regulatory & Medical Affairs Regulatory affairs and medical affairs support covering market authorization, lifecycle maintenance, and medical/scientific engagement across MENA health authorities. Intended for pharma and biotech manufacturers seeking compliant regional filings and medical-scientific support.
- Distribution & Supply Chain Pharmaceutical distribution and supply chain management across Saudi Arabia, UAE, Tunisia, and Egypt. Intended for pharma and biotech principals that need regional logistics and last-mile delivery without a local affiliate.
- Full Agency Management End-to-end commercialization of pharmaceutical products on behalf of partners across MENA, combining licensing, regulatory, distribution, and commercial execution under a single mandate. Intended for pharma and biotech principals that want an asset-light regional presence.
- Advisory & Consultancy Strategic advisory and consultancy supporting pharmaceutical and biotech partners on MENA market entry, access strategy, and unmet medical/commercial need identification. Intended for pharma and biotech decision-makers evaluating regional expansion.
Quantifiable outcome
- Supplying customers in over 8 countries
- +2 more outcomes
Companies that use AcedrA BioPharmaceuticals
Customer profileSegments4 records
Ideal customer profiles1 record
AcedrA BioPharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AcedrA BioPharmaceuticals partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
AcedrA BioPharmaceuticals competitors and assessment
Company assessmentRegional players
- EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharmaceutical manufacturers with regional MENA reach. Comparable to AcedrA as a regional specialty pharma player, though primarily a manufacturer and Egypt-anchored.
- Pharma International Co: Jordanian pharmaceutical manufacturer with established distribution across the Levant and selected Gulf markets. Comparable to AcedrA's regional specialty pharma distribution model, although its core manufacturing footprint is in Jordan.
Direct peers
- Hikma Pharmaceuticals: Jordan-headquartered specialty and generics pharma company with substantial MENA manufacturing and distribution operations. Comparable to AcedrA as a regional specialty pharma player combining proprietary products with regional distribution across KSA, UAE, and North Africa.
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and regional distributor serving the MENA market with branded generics and specialty products. Comparable to AcedrA's UAE hub and MENA distribution focus, although Julphar is also a manufacturer.
- Avalon Pharma: Privately held Saudi pharmaceutical company focused on specialty and niche therapy areas with MENA distribution. Comparable to AcedrA's specialty pharma focus and KSA-centric operational footprint.
- Tabuk Pharmaceuticals: Saudi pharmaceutical manufacturer and distributor with strong domestic presence and selected MENA exports. Comparable to AcedrA as a Saudi-anchored specialty pharma company serving regional healthcare providers.
- Mundipharma: Independent specialty pharma company with established MENA commercial operations focused on pain, respiratory, and specialty therapy areas. Comparable to AcedrA's specialty pharma distribution and access focus, with similar emphasis on bringing originator products into regional markets.
Others
- IQVIA MENA: Global life sciences services and data company with MENA operations spanning commercial outsourcing, regulatory support, and market access consulting. Comparable to AcedrA's regulatory, advisory, and market access services as a much larger, globally backed incumbent.
Broad incumbents
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): One of the largest publicly listed Saudi pharmaceutical companies, with broader branded generics and OTC portfolios than AcedrA. Comparable as a KSA-headquartered pharma operator, but operates at significantly larger scale and as a manufacturer rather than a services-led distributor.
Emerging players
- Clinart (MENA CRO): Regional clinical research organization serving pharma and biotech sponsors across MENA. Comparable to AcedrA on the services side (regulatory affairs, clinical support) rather than distribution, and overlaps in providing MENA market entry support to biotech clients.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AcedrA BioPharmaceuticals social profiles
Digital presenceAcedrA BioPharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
AcedrA BioPharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
AcedrA BioPharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AcedrA BioPharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AcedrA BioPharmaceuticals
What does AcedrA BioPharmaceuticals do?
AcedrA BioPharmaceuticals is a regional pharmaceutical services partner that helps pharmaceutical and biotechnology companies commercialize and provide access to their products across the MENA region. Its service portfolio spans in-licensing, early and managed access programs, regulatory and medical affairs, distribution and supply chain management, full agency management (commercializing products on behalf of partners), and strategic advisory services addressing unmet medical and commercial needs.
Is AcedrA BioPharmaceuticals a public or private company?
AcedrA BioPharmaceuticals is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AcedrA BioPharmaceuticals founded?
AcedrA BioPharmaceuticals was founded in 2017. It employs 51 to 100 people.
Where is AcedrA BioPharmaceuticals based?
AcedrA BioPharmaceuticals is headquartered in Riyadh, Saudi Arabia, in the Middle East region.
How does AcedrA BioPharmaceuticals make money?
Six revenue lines are on record. Licensing Services are the primary driver. The others are managed & Early Access Programs, regulatory & Medical Affairs Management, distribution & Supply Chain, full Agency Management and advisory & Consultancy.
Who are AcedrA BioPharmaceuticals's main competitors?
Regional players on record are EIPICO (Egyptian International Pharmaceutical Industries Company) and Pharma International Co. Direct peers are Hikma Pharmaceuticals, Julphar (Gulf Pharmaceutical Industries), Avalon Pharma, Tabuk Pharmaceuticals and Mundipharma. IQVIA MENA is listed as an others. SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation) is listed as a broad incumbent. Clinart (MENA CRO) is listed as an emerging player.
Does AcedrA BioPharmaceuticals have an API?
No public API is recorded for AcedrA BioPharmaceuticals.
What industry is AcedrA BioPharmaceuticals in?
AcedrA BioPharmaceuticals's product category is Pharmaceutical Services. Its primary akta.pro industry code is HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic), with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 54 and its SIC code is 5122.